OTC Switch Actual Use Studies May Not Be Worth The Expense, Juhl Suggests
This article was originally published in The Tan Sheet
Executive Summary
Actual use studies supporting Rx-to-OTC switch applications provide questionable benefit beyond what is learned in label comprehension studies, according to former Nonprescription Drugs Advisory Committee Chair Randy Juhl, PhD